Kayentis, a Grenoble, France-based provider of digital data capture systems for clinical trials, raised €7M (approx. $8.3M) in growth funding.
The round was led by historical investors Extens and LBO France with participation from new backer Bpifrance.
The company intends to use the funds to accelerate R&D activities, enriching its new eCOA platform – Clin’form3 – with new functionalities and services to support post-COVID ‘new normal’ and decentralized clinical trials, to improve the experience of patients and investigator sites during clinical trials (enabling televisits, eConsent capability and integration with external devices including wearables) and intensify US developments, initially by reinforcing the Boston-based US team, then expanding its footprint across North America.
Led by Guillaume Juge, CEO, Kayentis is a global provider of digital data capture technologies for sponsors, sites and patients in clinical trials. Active in clinical development since 2003, the company has, within the last ten years, specialized in electronic Clinical Outcome Assessment (eCOA) solutions for phase II/III research in a broad range of therapeutic areas. It is now expanding in the field of hybrid trials. Advances in its digital technologies include new functions and apps that facilitate integration with other clinical databases, provide flexible adaptation to clinical workflows and improve patient experience. To date, Kayentis has conducted digital data collection for over 220 clinical trials in 79 countries (13,000 sites and 80,000 patients); employing 120 different languages.
Headquartered in France, the company also has operations in Boston (MA) and in Tokyo (Japan).